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Introduction
• Surgical resection remains the gold standard treatment for clinically localized renal cell carcinoma 
(RCC)
• Rates of recurrence continue to remain significant – estimations noted to range from 20 – 30 %
• Most contemporary guidelines use risk-stratified models as a foundation for post-operative surveillance 
recommendations 
• The guidelines for post-operative surveillance are clear and structured for patients within the first 5 
years following surgery
• There are no clear indications nor instruction for the follow-up protocols following 5 years after surgery
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Methods
• Patient Cohort: Post-hoc analysis of 1,943 total patients within Eastern 
Cooperative Oncology Group - American College of Radiology Imaging Network 
(ECOG-ACRIN) E2805 Trial cohort 
• Primary Outcome: Rates of recurrence following surgical resection
• Post-operative recurrence rates determined using cumulative incidence
• 36-month rates of recurrence assessed for patients whom did not have recurrence at 
sequential intervals following surgery 
• Secondary Outcome: Clinical and pathological features predictive of recurrence at 
0-months and 60-months
• Covariates: age, sex, race, T stage, N stage, M stage, Fuhrman grade, 
histology, surgical approach (open vs. laparoscopic), type of nephrectomy 
(nephron-sparring vs. radical), ECOG performance status 
Results
• Median (IQR) age was 56 (49 - 64) 
• 730 patients developed recurrence
• T3/T4 (58.8%) most common
• Most underwent radical nephrectomy (95.0%) 
• Majority underwent open approach (57.1%) 
• 36-month cumulative incidence of recurrence
• 0 months - 31.1%
• 12 months - 26.0%
• 24 months - 18.8% 
• 36 months - 16.1% 
• 48 months - 18.9%
• 60 months - 20.3%
Results
Multivariate Competing Risks at 0 - months Multivariate Competing Risks at 60 - months
Conclusions
Our results support the necessity of long-term follow-up in all
intermediate- to high-risk RCC patient whom were treated surgically.
Although the exact duration and stop date of follow-up remains to be
established, the data supports follow-up beyond 5-years and likely up
to 8 years following surgery. Larger prospective studies are still
required to identify the optimal surveillance protocol and duration of
follow-up
